Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 749

1.

Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells.

Ruck T, Pfeuffer S, Schulte-Mecklenbeck A, Gross CC, Lindner M, Metze D, Ehrchen J, Sondermann W, Pul R, Kleinschnitz C, Wiendl H, Meuth SG, Klotz L.

Neurology. 2018 Nov 7. pii: 10.1212/WNL.0000000000006648. doi: 10.1212/WNL.0000000000006648. [Epub ahead of print]

PMID:
30404783
2.

Differential capability of metabolic substrates to promote hepatocellular lipid accumulation.

Hoang NA, Richter F, Schubert M, Lorkowski S, Klotz LO, Steinbrenner H.

Eur J Nutr. 2018 Oct 27. doi: 10.1007/s00394-018-1847-2. [Epub ahead of print]

PMID:
30368556
3.

Correction to: Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials.

Schultz NM, Shore ND, Chowdhury S, Klotz LH, Concepcion RS, Penson DF, Karsh LI, Yang H, Brown BA, Barlev A, Flanders SC.

BMC Urol. 2018 Oct 1;18(1):84. doi: 10.1186/s12894-018-0397-5.

4.

Nuclear trapping of inactive FOXO1 by the Nrf2 activator diethyl maleate.

Gille A, Turkistani A, Tsitsipatis D, Hou X, Tauber S, Hamann I, Urban N, Erler K, Steinbrenner H, Klotz LO.

Redox Biol. 2018 Sep 14;20:19-27. doi: 10.1016/j.redox.2018.09.010. [Epub ahead of print]

5.
6.

The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation.

Ouellet V, Aprikian A, Bergeron A, Brimo F, Bristow RG, Chevalier S, Drachenberg D, Fazli L, Fleshner NE, Gleave M, Karakiewicz P, Klotz L, Lacombe L, Lattouf JB, van der Kwast T, Squire JA, Latour M, Trudel D, Mes-Masson AM, Saad F.

BMC Urol. 2018 Sep 10;18(1):78. doi: 10.1186/s12894-018-0392-x.

7.

Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials.

Schultz NM, Shore ND, Chowdhury S, Klotz LH, Concepcion RS, Penson DF, Karsh LI, Yang H, Brown BA, Barlev A, Flanders SC.

BMC Urol. 2018 Sep 6;18(1):77. doi: 10.1186/s12894-018-0387-7. Erratum in: BMC Urol. 2018 Oct 1;18(1):84.

8.

Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations.

Crawford ED, Heidenreich A, Lawrentschuk N, Tombal B, Pompeo ACL, Mendoza-Valdes A, Miller K, Debruyne FMJ, Klotz L.

Prostate Cancer Prostatic Dis. 2018 Aug 21. doi: 10.1038/s41391-018-0079-0. [Epub ahead of print]

PMID:
30131604
9.

Discriminative power of intra-retinal layers in early multiple sclerosis using 3D OCT imaging.

Seitz CB, Droby A, Zaubitzer L, Krämer J, Paradis M, Klotz L, Wiendl H, Groppa S, Meuth SG, Zipp F, Fleischer V.

J Neurol. 2018 Oct;265(10):2284-2294. doi: 10.1007/s00415-018-8988-3. Epub 2018 Aug 2.

PMID:
30073502
10.

Nur77 serves as a molecular brake of the metabolic switch during T cell activation to restrict autoimmunity.

Liebmann M, Hucke S, Koch K, Eschborn M, Ghelman J, Chasan AI, Glander S, Schädlich M, Kuhlencord M, Daber NM, Eveslage M, Beyer M, Dietrich M, Albrecht P, Stoll M, Busch KB, Wiendl H, Roth J, Kuhlmann T, Klotz L.

Proc Natl Acad Sci U S A. 2018 Aug 21;115(34):E8017-E8026. doi: 10.1073/pnas.1721049115. Epub 2018 Aug 2.

PMID:
30072431
11.

Immune Cell Profiling During Switching from Natalizumab to Fingolimod Reveals Differential Effects on Systemic Immune-Regulatory Networks and on Trafficking of Non-T Cell Populations into the Cerebrospinal Fluid-Results from the ToFingo Successor Study.

Lohmann L, Janoschka C, Schulte-Mecklenbeck A, Klinsing S, Kirstein L, Hanning U, Wirth T, Schneider-Hohendorf T, Schwab N, Gross CC, Eveslage M, Meuth SG, Wiendl H, Klotz L.

Front Immunol. 2018 Jul 9;9:1560. doi: 10.3389/fimmu.2018.01560. eCollection 2018.

12.

Furosemide and Albumin for Diuresis of Edema (FADE): A parallel-group, blinded, pilot randomized controlled trial.

Oczkowski SJW, Klotz L, Mazzetti I, Alshamsi F, Chen ML, Foster G, Meade MO, Hamielec C.

J Crit Care. 2018 Dec;48:462-467. doi: 10.1016/j.jcrc.2018.07.020. Epub 2018 Jul 19.

PMID:
30037660
13.

Oncologic and functional outcome of partial gland ablation with HIFU for localized prostate cancer.

Bass R, Fleshner N, Finelli A, Barkin J, Zhang L, Klotz L.

J Urol. 2018 Jul 20. pii: S0022-5347(18)43550-1. doi: 10.1016/j.juro.2018.07.040. [Epub ahead of print]

PMID:
30036514
14.

Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A Post Hoc Analysis of the PR.7 Trial.

Toren P, Hoffman A, Ding K, Joncas FH, Turcotte V, Caron P, Pouliot F, Fradet Y, Lévesque É, Guillemette C, Klotz L.

Clin Cancer Res. 2018 Nov 1;24(21):5305-5312. doi: 10.1158/1078-0432.CCR-18-1187. Epub 2018 Jul 18.

PMID:
30021911
15.

Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial.

Klotz L, Loblaw A, Sugar L, Moussa M, Berman DM, Van der Kwast T, Vesprini D, Milot L, Kebabdjian M, Fleshner N, Ghai S, Chin J, Pond GR, Haider M.

Eur Urol. 2018 Jul 13. pii: S0302-2838(18)30450-0. doi: 10.1016/j.eururo.2018.06.025. [Epub ahead of print]

PMID:
30017404
16.

Independent Heath Facility Meets Cancer Care Ontario and Canadian Association of Gastroenterology Guidelines for Endoscopic Procedure Wait Times While Meeting Quality Indicators: A Retrospective Review.

Kegel F, Sne N, Rice T, Joy E, Shahsavar S, Collins CA, Gagarine M, Allard-Coutu A, Klotz L, Coates A, Kahnamoui K, Simunovic M.

Can J Gastroenterol Hepatol. 2018 Jun 3;2018:4708270. doi: 10.1155/2018/4708270. eCollection 2018.

17.

Surveillance after prostate focal therapy.

Tay KJ, Amin MB, Ghai S, Jimenez RE, Kench JG, Klotz L, Montironi R, Muto S, Rastinehad AR, Turkbey B, Villers A, Polascik TJ.

World J Urol. 2018 Jun 9. doi: 10.1007/s00345-018-2363-y. [Epub ahead of print]

PMID:
29948045
18.

Persistence of de novo donor specific HLA-Antibodies after lung transplantation: a potential marker of decreased patient survival.

Schmitzer M, Winter H, Kneidinger N, Meimarakis G, Dick A, Schramm R, Klotz LV, Preissler G, Strobl N, von Dossow V, Schneider C, Weig T, Hatz R, Kauke T.

HLA. 2018 Jun 10. doi: 10.1111/tan.13306. [Epub ahead of print]

PMID:
29888557
19.

Peroxisome Proliferator-Activated Receptor-γ Modulates the Response of Macrophages to Lipopolysaccharide and Glucocorticoids.

Heming M, Gran S, Jauch SL, Fischer-Riepe L, Russo A, Klotz L, Hermann S, Schäfers M, Roth J, Barczyk-Kahlert K.

Front Immunol. 2018 May 8;9:893. doi: 10.3389/fimmu.2018.00893. eCollection 2018.

20.

Stratifying Risk for Men With Low-Volume Intermediate-Risk Prostate Cancer.

Klotz L.

JAMA Oncol. 2018 Aug 1;4(8):1133. doi: 10.1001/jamaoncol.2018.0748. No abstract available.

PMID:
29852034
21.

Insulin suppresses the production of fibroblast growth factor 23 (FGF23).

Bär L, Feger M, Fajol A, Klotz LO, Zeng S, Lang F, Hocher B, Föller M.

Proc Natl Acad Sci U S A. 2018 May 29;115(22):5804-5809. doi: 10.1073/pnas.1800160115. Epub 2018 May 14.

PMID:
29760049
22.

The future of active surveillance.

Klotz L.

Transl Androl Urol. 2018 Apr;7(2):256-259. doi: 10.21037/tau.2018.01.12. No abstract available.

23.

Testosterone suppression in the treatment of recurrent or metastatic prostate cancer - A Canadian consensus statement.

Klotz L, Shayegan B, Guillemette C, Collins LL, Gotto G, Guérette D, Jammal MP, Pickles T, Richard PO, Saad F.

Can Urol Assoc J. 2018 Feb;12(2):30-37. doi: 10.5489/cuaj.5116. Epub 2017 Dec 19.

24.

Prostate cancer prevention: proof is elusive.

Klotz L.

BJU Int. 2018 Apr;121(4):487-488. doi: 10.1111/bju.14184. No abstract available.

PMID:
29603894
25.

Mechanisms underlying lesion development and lesion distribution in CNS autoimmunity.

Lindner M, Klotz L, Wiendl H.

J Neurochem. 2018 Jul;146(2):122-132. doi: 10.1111/jnc.14339. Epub 2018 May 16. Review.

PMID:
29574788
26.

MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis.

Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, Briganti A, Budäus L, Hellawell G, Hindley RG, Roobol MJ, Eggener S, Ghei M, Villers A, Bladou F, Villeirs GM, Virdi J, Boxler S, Robert G, Singh PB, Venderink W, Hadaschik BA, Ruffion A, Hu JC, Margolis D, Crouzet S, Klotz L, Taneja SS, Pinto P, Gill I, Allen C, Giganti F, Freeman A, Morris S, Punwani S, Williams NR, Brew-Graves C, Deeks J, Takwoingi Y, Emberton M, Moore CM; PRECISION Study Group Collaborators.

N Engl J Med. 2018 May 10;378(19):1767-1777. doi: 10.1056/NEJMoa1801993. Epub 2018 Mar 18.

PMID:
29552975
27.

A Phase II, Randomized, Multicenter Study Comparing 10 Months versus 4 Months of Degarelix Therapy in Prolonging the Off Treatment Interval in Men with Localized Prostate Cancer Receiving Intermittent Androgen Deprivation Therapy for Biochemical Recurrence following Radical Local Therapy.

Klotz L, Loblaw A, Siemens R, Ouellette P, Kapoor A, Kebabdjian M, Zhang L, Saad F; Canadian Urology Research Consortium.

J Urol. 2018 Aug;200(2):335-343. doi: 10.1016/j.juro.2018.03.010. Epub 2018 Mar 11.

PMID:
29534997
28.

Treatment choices and neuropsychological symptoms of a large cohort of early MS.

von Bismarck O, Dankowski T, Ambrosius B, Hessler N, Antony G, Ziegler A, Hoshi MM, Aly L, Luessi F, Groppa S, Klotz L, Meuth SG, Tackenberg B, Stoppe M, Then Bergh F, Tumani H, Kümpfel T, Stangel M, Heesen C, Wildemann B, Paul F, Bayas A, Warnke C, Weber F, Linker RA, Ziemann U, Zettl UK, Zipp F, Wiendl H, Hemmer B, Gold R, Salmen A.

Neurol Neuroimmunol Neuroinflamm. 2018 Mar 1;5(3):e446. doi: 10.1212/NXI.0000000000000446. eCollection 2018 May.

29.

FOXO1 cysteine-612 mediates stimulatory effects of the coregulators CBP and PGC1α on FOXO1 basal transcriptional activity.

Tsitsipatis D, Gopal K, Steinbrenner H, Klotz LO.

Free Radic Biol Med. 2018 Apr;118:98-107. doi: 10.1016/j.freeradbiomed.2018.02.034. Epub 2018 Mar 2.

PMID:
29496617
30.

Sex bias in MHC I-associated shaping of the adaptive immune system.

Schneider-Hohendorf T, Görlich D, Savola P, Kelkka T, Mustjoki S, Gross CC, Owens GC, Klotz L, Dornmair K, Wiendl H, Schwab N.

Proc Natl Acad Sci U S A. 2018 Feb 27;115(9):2168-2173. doi: 10.1073/pnas.1716146115. Epub 2018 Feb 12.

31.

Personal prostate-specific antigen screening and treatment choices for localized prostate cancer among expert physicians.

Wallis C, Cheung D, Klotz L, Chalasani V, Leao R, Garisto J, Morton G, Nam R, Tannock I, Satkunasivam R.

Can Urol Assoc J. 2018 Feb;12(2):E59-E63. doi: 10.5489/cuaj.4736. Epub 2017 Dec 1.

32.

Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options.

Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, Freedland SJ, Greene K, Klotz LH, Makarov DV, Nelson JB, Rodrigues G, Sandler HM, Taplin ME, Treadwell JR.

J Urol. 2018 Apr;199(4):990-997. doi: 10.1016/j.juro.2018.01.002. Epub 2018 Jan 10.

PMID:
29331546
33.

Infectious risk stratification in multiple sclerosis patients receiving immunotherapy.

Graf J, Leussink VI, Dehmel T, Ringelstein M, Goebels N, Adams O, MacKenzie CR, Warnke C, Feldt T, Lammerskitten A, Klotz L, Meuth S, Wiendl H, Hartung HP, Aktas O, Albrecht P.

Ann Clin Transl Neurol. 2017 Nov 24;4(12):909-914. doi: 10.1002/acn3.491. eCollection 2017 Dec.

34.

Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit-Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA.

Ziemssen T, Lang M, Tackenberg B, Schmidt S, Albrecht H, Klotz L, Haas J, Lassek C, Medin J, Cornelissen C; PANGAEA study group.

Neurotherapeutics. 2018 Jan;15(1):190-199. doi: 10.1007/s13311-017-0595-y.

35.

A single mitochondrial DNA deletion accurately detects significant prostate cancer in men in the PSA 'grey zone'.

Creed J, Klotz L, Harbottle A, Maggrah A, Reguly B, George A, Gnanapragasm V.

World J Urol. 2018 Mar;36(3):341-348. doi: 10.1007/s00345-017-2152-z. Epub 2017 Dec 16.

36.

Assessment of Serum microRNA Biomarkers to Predict Reclassification of Prostate Cancer in Patients on Active Surveillance.

Liu RSC, Olkhov-Mitsel E, Jeyapala R, Zhao F, Commisso K, Klotz L, Loblaw A, Liu SK, Vesprini D, Fleshner NE, Bapat B.

J Urol. 2018 Jun;199(6):1475-1481. doi: 10.1016/j.juro.2017.12.006. Epub 2017 Dec 12.

PMID:
29246734
37.

Total energy expenditure and vigorous-intensity physical activity are associated with reduced odds of reclassification among men on active surveillance.

Guy DE, Vandersluis A, Klotz LH, Fleshner N, Kiss A, Parker C, Venkateswaran V.

Prostate Cancer Prostatic Dis. 2018 Jun;21(2):187-195. doi: 10.1038/s41391-017-0010-0. Epub 2017 Dec 14.

PMID:
29242596
38.

Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options.

Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, Freedland SJ, Greene K, Klotz LH, Makarov DV, Nelson JB, Rodrigues G, Sandler HM, Taplin ME, Treadwell JR.

J Urol. 2018 Mar;199(3):683-690. doi: 10.1016/j.juro.2017.11.095. Epub 2017 Dec 15.

PMID:
29203269
39.
40.

Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts.

Inoue LYT, Lin DW, Newcomb LF, Leonardson AS, Ankerst D, Gulati R, Carter HB, Trock BJ, Carroll PR, Cooperberg MR, Cowan JE, Klotz LH, Mamedov A, Penson DF, Etzioni R.

Ann Intern Med. 2018 Jan 2;168(1):1-9. doi: 10.7326/M17-0548. Epub 2017 Nov 28.

41.

Intraoperative Anesthetic Management of Lung Transplantation: Center-Specific Practices and Geographic and Centers Size Differences.

Tomasi R, Betz D, Schlager S, Kammerer T, Hoechter DJ, Weig T, Slinger P, Klotz LV, Zwißler B, Marczin N, von Dossow V.

J Cardiothorac Vasc Anesth. 2018 Feb;32(1):62-69. doi: 10.1053/j.jvca.2017.05.025. Epub 2017 May 17.

PMID:
29174123
42.

Corrigendum to "European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS)" [Redox Biol. 13 (2017) 94-162].

Egea J, Fabregat I, Frapart YM, Ghezzi P, Görlach A, Kietzmann T, Kubaichuk K, Knaus UG, Lopez MG, Olaso-Gonzalez G, Petry A, Schulz R, Vina J, Winyard P, Abbas K, Ademowo OS, Afonso CB, Andreadou I, Antelmann H, Antunes F, Aslan M, Bachschmid MM, Barbosa RM, Belousov V, Berndt C, Bernlohr D, Bertrán E, Bindoli A, Bottari SP, Brito PM, Carrara G, Casas AI, Chatzi A, Chondrogianni N, Conrad M, Cooke MS, Costa JG, Cuadrado A, My-Chan Dang P, De Smet B, Debelec-Butuner B, Dias IHK, Dunn JD, Edson AJ, El Assar M, El-Benna J, Ferdinandy P, Fernandes AS, Fladmark KE, Förstermann U, Giniatullin R, Giricz Z, Görbe A, Griffiths H, Hampl V, Hanf A, Herget J, Hernansanz-Agustín P, Hillion M, Huang J, Ilikay S, Jansen-Dürr P, Jaquet V, Joles JA, Kalyanaraman B, Kaminskyy D, Karbaschi M, Kleanthous M, Klotz LO, Korac B, Korkmaz KS, Koziel R, Kračun D, Krause KH, Křen V, Krieg T, Laranjinha J, Lazou A, Li H, Martínez-Ruiz A, Matsui R, McBean GJ, Meredith SP, Messens J, Miguel V, Mikhed Y, Milisav I, Milković L, Miranda-Vizuete A, Mojović M, Monsalve M, Mouthuy PA, Mulvey J, Münzel T, Muzykantov V, Nguyen ITN, Oelze M, Oliveira NG, Palmeira CM, Papaevgeniou N, Pavićević A, Pedre B, Peyrot F, Phylactides M, Pircalabioru GG, Pitt AR, Poulsen HE, Prieto I, Rigobello MP, Robledinos-Antón N, Rodríguez-Mañas L, Rolo AP, Rousset F, Ruskovska T, Saraiva N, Sasson S, Schröder K, Semen K, Seredenina T, Shakirzyanova A, Smith GL, Soldati T, Sousa BC, Spickett CM, Stancic A, Stasia MJ, Steinbrenner H, Stepanić V, Steven S, Tokatlidis K, Tuncay E, Turan B, Ursini F, Vacek J, Vajnerova O, Valentová K, Van Breusegem F, Varisli L, Veal EA, Yalçın AS, Yelisyeyeva O, Žarković N, Zatloukalová M, Zielonka J, Touyz RM, Papapetropoulos A, Grune T, Lamas S, Schmidt HHHW, Di Lisa F, Daiber A.

Redox Biol. 2018 Apr;14:694-696. doi: 10.1016/j.redox.2017.10.001. Epub 2017 Oct 26. No abstract available.

43.

Contemporary Active Surveillance: Candidate Selection, Follow-up Tools, and Expected Outcomes.

Perlis N, Klotz L.

Urol Clin North Am. 2017 Nov;44(4):565-574. doi: 10.1016/j.ucl.2017.07.005. Review.

PMID:
29107273
44.
45.

Dual action by fumaric acid esters synergistically reduces adhesion to human endothelium.

Breuer J, Herich S, Schneider-Hohendorf T, Chasan AI, Wettschureck N, Gross CC, Loser K, Zarbock A, Roth J, Klotz L, Wiendl H, Schwab N.

Mult Scler. 2017 Oct 1:1352458517735189. doi: 10.1177/1352458517735189. [Epub ahead of print]

PMID:
28984166
46.

Prostatectomy versus Observation for Early Prostate Cancer.

Wallis CJD, Klotz L.

N Engl J Med. 2017 Sep 28;377(13):1301-2. doi: 10.1056/NEJMc1710384. No abstract available.

PMID:
28976174
47.

Liver X receptor activation promotes differentiation of regulatory T cells.

Herold M, Breuer J, Hucke S, Knolle P, Schwab N, Wiendl H, Klotz L.

PLoS One. 2017 Sep 19;12(9):e0184985. doi: 10.1371/journal.pone.0184985. eCollection 2017.

48.

Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice.

Berer K, Gerdes LA, Cekanaviciute E, Jia X, Xiao L, Xia Z, Liu C, Klotz L, Stauffer U, Baranzini SE, Kümpfel T, Hohlfeld R, Krishnamoorthy G, Wekerle H.

Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):10719-10724. doi: 10.1073/pnas.1711233114. Epub 2017 Sep 11.

49.

Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters.

Schwab N, Schneider-Hohendorf T, Hoyt T, Gross CC, Meuth SG, Klotz L, Foley JF, Wiendl H.

Mult Scler. 2018 Apr;24(5):563-573. doi: 10.1177/1352458517728814. Epub 2017 Aug 29.

PMID:
28847222
50.

Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial.

Siemens DR, Klotz L, Heidenreich A, Chowdhury S, Villers A, Baron B, van Os S, Hasabou N, Wang F, Lin P, Shore ND.

J Urol. 2018 Jan;199(1):147-154. doi: 10.1016/j.juro.2017.08.080. Epub 2017 Aug 19.

PMID:
28827103

Supplemental Content

Support Center